BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24050506)

  • 1. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?
    Kalpadakis C; Pangalis GA; Vassilakopoulos TP; Sachanas S; Angelopoulou MK
    Leuk Lymphoma; 2014 Jul; 55(7):1463-70. PubMed ID: 24050506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?
    Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Vassilakopoulos TP
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):65-72. PubMed ID: 29452668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
    Bennett M; Schechter GP
    Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment.
    Lenglet J; Traullé C; Mounier N; Benet C; Munoz-Bongrand N; Amorin S; Noguera ME; Traverse-Glehen A; Ffrench M; Baseggio L; Felman P; Callet-Bauchu E; Brice P; Berger F; Salles G; Brière J; Coiffier B; Thieblemont C
    Leuk Lymphoma; 2014 Aug; 55(8):1854-60. PubMed ID: 24206091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
    Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
    Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of splenic marginal zone lymphoma.
    Kalpadakis C; Pangalis GA; Angelopoulou MK; Vassilakopoulos TP
    Best Pract Res Clin Haematol; 2017; 30(1-2):139-148. PubMed ID: 28288709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.
    Xing KH; Kahlon A; Skinnider BF; Connors JM; Gascoyne RD; Sehn LH; Savage KJ; Slack GW; Shenkier TN; Klasa R; Gerrie AS; Villa D
    Br J Haematol; 2015 May; 169(4):520-7. PubMed ID: 25854936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center.
    de Pádua Covas Lage LA; Dos Santos FFC; Levy D; Moreira FR; Couto SCF; Culler HF; de Oliveira Costa R; Rocha V; Pereira J
    BMC Cancer; 2020 Aug; 20(1):717. PubMed ID: 32746790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma.
    Olszewski AJ
    Am J Hematol; 2012 Nov; 87(11):E119-22. PubMed ID: 22887176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laparoscopic splenectomy for treatment of splenic marginal zone lymphoma.
    Wu Z; Zhou J; Wang X; Li YB; Niu T; Peng B
    World J Gastroenterol; 2013 Jun; 19(24):3854-60. PubMed ID: 23840125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Still a role for surgery as first-line therapy of splenic marginal zone lymphoma? Results of a prospective observational study.
    Pata G; Bartoli M; Damiani E; Solari S; Anastasia A; Pagani C; Tucci A
    Int J Surg; 2017 May; 41():143-149. PubMed ID: 28366762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
    Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
    Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological features of splenic tumours of lymphoid tissue.
    Chen DB; Shen DH; Yang SM; Fang XZ
    Pathol Res Pract; 2018 Dec; 214(12):1952-1958. PubMed ID: 30087035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
    Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
    Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.
    Olszewski AJ; Ali S
    Ann Hematol; 2014 Mar; 93(3):449-58. PubMed ID: 24057925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.
    Ishiguro K; Sasaki Y; Takagi Y; Niinuma T; Suzuki H; Tokino T; Hayashi T; Takahashi T; Igarashi T; Matsuno Y
    Medicine (Baltimore); 2020 Aug; 99(35):e21938. PubMed ID: 32871937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.
    Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Kontopidou FN; Yiakoumis X; Kokoris SI; Dimitriadou EM; Dimopoulou MN; Moschogiannis M; Korkolopoulou P; Kyrtsonis MC; Siakantaris MP; Papadaki T; Tsaftaridis P; Plata E; Papadaki HE; Vassilakopoulos TP
    Oncologist; 2013; 18(2):190-7. PubMed ID: 23345547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress on Treatment of Splenic Marginal Zone Lymphoma-Review].
    Wu L; Tian C; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):600-603. PubMed ID: 28446319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
    Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
    Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splenic marginal zone lymphoma: from genetics to management.
    Arcaini L; Rossi D; Paulli M
    Blood; 2016 Apr; 127(17):2072-81. PubMed ID: 26989207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.